Sphingolipid Signaling and Complement Activation in Glioblastoma: A Promising Avenue for Therapeutic Intervention.
Biochem (Basel)
; 4(2): 126-143, 2024 Jun.
Article
in En
| MEDLINE
| ID: mdl-38894892
ABSTRACT
Glioblastoma is the most common and aggressive type of malignant brain tumor with a poor prognosis due to the lack of effective treatment options. Therefore, new treatment options are required. Sphingolipids are essential components of the cell membrane, while complement components are integral to innate immunity, and both play a critical role in regulating glioblastoma survival signaling. This review focuses on recent studies investigating the functional roles of sphingolipid metabolism and complement activation signaling in glioblastoma. It also discusses how targeting these two systems together may emerge as a novel therapeutic approach.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Biochem (Basel)
Year:
2024
Document type:
Article
Affiliation country:
Estados Unidos
Publication country:
CH
/
SUIZA
/
SUÍÇA
/
SWITZERLAND